

1 **BSR/PDA Standard 05-201x, Consensus Method for Rating 0.1**
2 **Mycoplasma Reduction Filters**

3 **Draft stage**
4

5 BSR/PDA Standard 05-201x, Consensus Method for Rating 0.1
6 Mycoplasma Reduction Filters

7 Authors

Martha Folmsbee (Chair)
Pall

Kathleen Souza (Co Chair)
Millipore Sigma

Maria Reyes Candau-Chacon
FDA

Gerhard Haake
Sartorius Stedim Biotech GmbH

Patricia Hughes
FDA

Anvesh Jupaka
Microbiologist

Robert Kiss
Sutro Biopharma, Inc.

Jill Mariano
Bionique Testing Labs

Jerry Martin
Consultant

Leesa McBurnie
Meissner Filtration Products

Laura Okhio- Seaman
Sartorius Stedim Biotech

Sandip V. Patel
Microbiologist

Barbara Potts
Potts and Nelson Consulting

8 **Contents**

9 **Introductioniv**

10 **1 Scope 1**

11 **2 Normative References..... 1**

12 **3 Terms and Definitions 2**

13 **4 Acronyms and Abbreviations 3**

14 **5 Mycoplasma Filtration 4**

15 **5.1 Summary of mycoplasma challenge testing..... 4**

16 **5.2 Test validity criteria 4**

17 **5.3 Summary of test parameters 5**

18 **6 Method..... 5**

19 **6.1 Material and equipment..... 6**

20 **6.1.1 Preparation of media and buffer 7**

21 **6.2 Preparation of challenge microorganism 8**

22 **6.2.1 Preparation of the challenge suspension..... 8**

23 **6.2.2 Challenge test apparatus..... 9**

24 **6.3 Reporting results..... 11**

25 **6.4 Test acceptance criteria..... 11**

26 **7 Bibliography..... 13**

27

28 Introduction

29 Mycoplasmas (trivial name for organisms of the class Mollicutes) are well-known microbial contaminants
30 found in biologic processes, particularly cell culture processes. Historical surveys of cell lines have found high
31 rates of mycoplasma contamination in research labs and production facilities [1, 2]. With their ability to
32 establish occult contaminations, mycoplasmas can evade conventional bioburden assays, and even lead to
33 changes in metabolism and phenotype of the cell culture, potentially impacting resultant product quality.

34 The absence of a rigid peptidoglycan-based bacterial cell wall enables mycoplasmas to pass through
35 sterilizing-grade (0.2 µm) and mycoplasma reduction-grade (0.1 µm) filters, potentially contaminating an
36 entire production process. Filters are rated based on performance and not on an absolute measure of pore size.
37 Because of these invasive capabilities, mycoplasma contamination has garnered special attention by
38 regulatory agencies, resulting in expectations for testing and risk-mitigation [3].

39 USP <1043> provides categories that are useful for assessing material risks associated with mycoplasma
40 contamination in raw materials [4]. Examples of contamination risks include:

- 41 • Process materials, which can provide a suitable environment for mycoplasma to remain
42 present at high levels for at least 6 months [5] ;
- 43 • Biological process fluids (typically containing either plant or animal-derived components),
44 prepared with 0.2 µm filtration without a heat inactivation step [6, 7].

45 The risk of contamination not only depends on the media, but also on where the material is used in the process
46 and whether the process contains subsequent purification (i.e., inactivation or removal) steps. Therefore,
47 pretreatment of raw materials (e.g., heat treatment or irradiation) should be considered, where appropriate.

48 In a biologics process, 0.1 µm filtration is often used in drug substance manufacturing as a mycoplasma
49 contamination prevention measure. This barrier approach, with risk reduction as the goal, is prevalent in the
50 mammalian cell culture industry. The concept is similar to bioburden reduction filtration used in protein
51 purification processes. For upstream barrier applications, such as cell culture media filtration, process-specific
52 mycoplasma reduction validation is generally not a regulatory expectation. However, based on a risk
53 assessment, an end user may evaluate a process-specific reduction of mycoplasma using the mycoplasma
54 consensus method as described in this standard and an article previously published in the *PDA Journal of*
55 *Science and Technology* [8].

56 For manufacturers of raw materials (e.g., serum) that wish to make an *Acholeplasma laidlawii* (*A. laidlawii*)
57 reduction claim based on filtration, validation of the mycoplasma removal filtration process should be
58 performed following the principles outlined in PDA Technical Report 26 [9]. In addition, manufacturers of
59 raw materials should also consider using the mycoplasma method described in this standard to grow the *A.*
60 *laidlawii* challenge organism for validation purposes.

61

62

63 BSR/PDA Standard 05-201x, Method for Rating 0.1 Mycoplasma
64 Reduction Filters

65 **1 Scope**

66 This test method establishes a standardized method for filter manufacturer rating of nominal 0.1 micron rated
67 filter membrane for retention of mycoplasma using 47 mm discs and using *A. laidlawii* as the test organism. It
68 is also necessary for the filter manufacturer to validate filter devices that may require testing a wide variety of
69 device sizes and configurations. Validation of the actual filter device is not addressed in this standard test
70 method. Any appropriate end-user validation and/or qualification of 0.1 micron rated filter devices incorporating
71 such membrane is also outside of the scope of this standard.

72 This test is intended to be used by the filter manufacturer to validate a mycoplasma-retentive filter within a
73 manufacturing process and to qualify a filter for a mycoplasma retentive claim. Validation of a drug
74 manufacturing process employing such filter must be done under applicable process-specific conditions.

75

76 **2 Normative References**

77 The following documents are referred to in the text in such a way that some or all of their content constitutes
78 requirements of this document. For dated references, only the edition cited applies. For undated references, the
79 latest edition of the referenced document (including any amendments) applies.

80 PDA Technical Report No. 75 Consensus Method for Rating 0.1µm Mycoplasma Reduction Filters (2016)
81 [10].

82

83 The Development of a Microbial Challenge Test with *Acholeplasma laidlawii* To Rate Mycoplasma-Retentive
84 Filters by Filter Manufacturers [8].

85

86 **3 Terms and Definitions**

- 87 • *Acholeplasma laidlawii*: *A. laidlawii* is a mycoplasma in class Mollicutes and order Acholeplasmatales.
- 88 • Challenge Concentration: The concentration in Colony Forming Units/mL of the test microorganism in
89 the challenge fluid.
- 90 • Challenge Fluid: The carrier fluid in which the test microorganism is suspended and delivered to the test
91 filter.
- 92 • Challenge Level: The number of test microorganisms applied to the test filter (per square centimeter) at
93 the completion of the challenge.
- 94 • Challenge Volume: The volume of challenge fluid applied to the test filter.
- 95 • Colony Forming Units (CFU): A single microorganism or an aggregate of many that forms a single
96 discrete colony on solid agar media after suitable incubation. Colony-forming units are used for bacterial
97 titer determination on solid media.
- 98 • Culture Medium: The nutritional medium which supports the growth of the given microorganism.
- 99 • Filter Rating: A numerical rating of Filter membrane performance based on the ability of the filter to
100 retain an appropriate model microorganism under given test conditions (generally based on ASTM F838)
101 [11].
- 102 • Pa: pascal. The International System of Units derived unit of pressure.
- 103 • Log Reduction Value (LRV): Titer Reduction (TR) expressed as a base 10 logarithm.
- 104 • Mycoplasma Buffer – Made up of sodium phosphate monobasic, sodium phosphate dibasic, and deionized
105 water as described in Table 2 below.
- 106 • Mycoplasma Reduction Filter: A filter that provides a log reduction value (or a titer reduction value) for a
107 specified test mycoplasma according to the PDA Mycoplasma Consensus Method. Typically, these filters
108 are also qualified as sterilizing grade filters.
- 109 • Positive control filter membrane (Penetration control): A control filter membrane with a larger pore size
110 rating than the test filter and used to demonstrate the penetrative ability of the test microorganism..
- 111 • Psid: Pound-force per square-inch differential: the pressure difference between the upstream (influent) and
112 downstream (effluent) sides of a filter.
- 113 • Sterilizing Grade Filter: Described in PDA Technical Report 26 and in FDA guidance as a filter that
114 reproducibly removes all *B. diminuta* test microorganisms from the process stream, producing a sterile
115 effluent [9,12-14].
- 116 • Titer reduction (TR): A measure of the degree to which a particular filter removes a microorganism under
117 specified test conditions. Calculated as the ratio of the total number of microorganisms used to challenge
118 the filter divided by the total number of microorganisms that passed through the filter:

$$TR = \frac{\text{Upstream microbial Titer} \times \text{Volume Applied} = \text{Total \# Influent Cells}}{\text{Downstream microbial Titer} \times \text{Volume Filtered} = \text{Total \# Effluent Cells}}$$

120
121
122

123 **4 Acronyms and Abbreviations**

124 CFU - Colony Forming Units

125 kPa – kilopascal

126 LRV - Log Reduction Value

127 MTFB Mycoplasma Task Force Broth

128 TR – Titer reduction

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150 **5 Mycoplasma Filtration**

151 Filter manufacturers use a bacterial challenge test to characterize filter membrane performance during product
152 development and manufacturing lot release. Key elements of the bacterial challenge test include the cultivation
153 and preparation of the bacterial suspension, and the appropriate penetration of the positive control by the
154 bacteria.

155 The bacterial challenge microorganism should provide a final minimum challenge level of 1.0×10^7 CFU/cm²
156 of test filter surface area [11]. For mycoplasma reduction filters, *Acholeplasma laidlawii* obtained from a
157 reputable collection, and qualified strain (see section **6.1, Materials, Table 1**) hereinafter referred to as *A.*
158 *laidlawii*, is used as the challenge microorganism. Like microorganisms of the genus *Mycoplasma*, *A. laidlawii*
159 has no cell wall and is deformable. This characteristic makes *A. laidlawii* capable of penetrating 0.2 µm filters
160 and some 0.1 µm filters at high challenge levels, providing a means of differentiating 0.1 µm filter retention
161 capabilities. In addition, unlike many mycoplasma, *A. laidlawii* is comparatively easy to grow, robust, non-
162 pathogenic, and is capable of being grown to high titers in a relatively short time. Standardized preparation
163 parameters and media ensures consistent performance across laboratories.

164 **5.1 Summary of mycoplasma challenge testing**

165 In mycoplasma challenge testing, the test microorganism is inoculated directly into the challenge fluid and
166 delivered to the test filter. The test microorganism is suspended in the challenge fluid at a concentration that
167 delivers a minimum challenge level of 1.0×10^7 CFU/cm² of test filter area. A sample of the influent challenge
168 fluid is titered to determine the actual challenge level. The concentration of the test microorganism in the effluent
169 is also determined, and the number of influent and effluent microorganisms are compared to evaluate the filter
170 membrane performance.

171 A mycoplasma growth broth (MTFB) is specified here to generate the test cells. However, the validated
172 protocol for generating the frozen stock used to inoculate that growth broth is not specified and is the
173 responsibility of the laboratory performing the work. A validated mycoplasma titer protocol is also the
174 responsibility of the laboratory performing the work.

175 A bacterial titer is defined as the suspended concentration of bacteria (or, in this case, mycoplasma) in
176 solution. It is generally necessary to perform dilutions when titering to ensure countable plates. For a
177 mycoplasma challenge, the challenge fluid is titered as per each laboratory's validated method.

178 After the challenge has been completed and the full effluent volume collected, the effluent is titered, using
179 dilutions, or it may simply be filter plated in its entirety without any dilution or titer. If little or no penetration
180 is expected, then filter plating of the entire effluent may be appropriate to evaluate retention. If filter plating is
181 expected to result in uncountable plates, then a titer with dilutions would be appropriate.

182 A microbial retention challenge test produces two possible outcomes through a test article demonstrated to
183 be integral: 1) no penetration of the filter by the test microorganism under the given test conditions, or 2) some
184 degree of penetration under the given test conditions.

185

186 **5.2 Test validity criteria**

187 It is expected that 0.1 µm filters will retain high levels of *A. laidlawii* during a challenge test. Therefore, a 0.2
188 µm filter positive penetration control is necessary to verify that the cells are cultivated appropriately and that
189 the challenge test is valid.

190 Penetration by the *A. laidlawii* challenge through a 0.2 µm rated filter as a positive penetration control confirms
191 the small size, monodispersion (unclumped cells), and the overall penetrative ability of the test mycoplasma.
192 As a result, the primary criterion for test validity is growth downstream of a 0.2 µm rated filter.

193 In a challenge test, the positive control filter must be tested in parallel with the test filter(s). This serves to
194 confirm the validity of the test at the time it is performed. Lack of mycoplasma penetration of the 0.2 µm positive
195 control filter invalidates the test. The lack of mycoplasma growth downstream of the 0.2 µm positive control
196 filter may be due to a lack of viability or penetrative ability of the test culture, or a below-specification challenge
197 concentration.

198 The challenge test is considered valid if the *A. laidlawii* challenge level used was at a minimum of $\geq 1.0 \times$
199 10^7 CFU/cm², the cells were monodispersed as outlined in Section 6.2.1, the positive control filter
200 demonstrated penetration, and the filter integrity tests (pre- and post-challenge) passed.

201 5.3 Summary of test parameters

202 The test parameters are as follows:

- 203 • Test microorganism: *Acholeplasma laidlawii*
- 204 • Challenge level: $\geq 1.0 \times 10^7$ CFU/cm²
- 205 • Test pressure: 30 psid (207 kPa)
- 206 • Challenge volume for a 47 mm disc: 200 mL
- 207 • Challenge fluid: Phosphate buffer
- 208 • Positive control (penetration control): 0.2 µm sterilizing grade filter
- 209 • Mycoplasma Task Force Broth (MTFB) for generating test cells

210 The culture medium and incubation conditions are as follows:

- 211 • Temperature of incubation: 37±2 °C
- 212 • Duration of incubation: 3 days
- 213 • Composition of the MTFB:
 - 214 – Mycoplasma Broth Base (beef heart infusion broth)
 - 215 – Yeast Extract
 - 216 – Horse Serum, heat inactivated

217 Although the culture medium is not fully chemically defined, cultivation in this medium consistently ensures
218 the production of highly penetrative cells [8]. Both the MTFB and selected solid medium must be shown to
219 have satisfactory nutritive properties to support the growth of *A. laidlawii* under the chosen incubation
220 conditions. However, prequalification of the medium does not completely eliminate—but rather reduces—the
221 risk of test invalidation due to a failure to penetrate even a minimally retentive filter. As previously stated, in an
222 actual test, the 0.2 µm positive control filter must be tested simultaneously (i.e., with the same culture batch on
223 the same day) with the test filter(s) and ultimately serves to validate the test at the time it is performed.


224

225 6 Method

226 The following procedure describes a method for performing a mycoplasma challenge test of 47 mm membrane
227 filter discs using *Acholeplasma laidlawii* as the test microorganism. A mycoplasma challenge test of
228 presumptive 0.1 µm rated filters is validated using 0.2 µm rated positive-penetration control filters. The 0.2 µm
229 rated filters are used to confirm the penetrative ability of the test mycoplasma cells produced by cultivation in
230 the recommended growth media as described in this method. The positive control is intended to be tested under
231 the same conditions with the same challenge suspension pool as the test articles. The 0.2 µm filter challenge
232 conditions should not compromise the ability of the 0.2µm control filter to detect inappropriate sized test
233 organisms.

234
235
236

Figure 1. Summary Workflow



237
238

239 **6.1 Material and equipment**

240 The equipment needed to perform the challenge test is listed in **Table 1**.

241

242 **Table 1 Material and equipment required**

Filters
<u>Test Article:</u> 47 mm sterilized test filter discs (presumptive 0.1 µm rating, possibly unrated)
<u>Positive penetration control filter disc(s):</u> 47 mm sterilized filter discs, 0.2 µm sterilizing grade Note: It is the responsibility of the laboratory conducting this test to select the challenge conditions, polymer, and brand of 0.2 µm sterilizing grade filter and to perform studies demonstrating suitability for this test.
<u>Assay Recovery Filters:</u> Sterile filter discs validated for use in <i>A. laidlawii</i> assay Note: It is the responsibility of the laboratory conducting this test to select the polymer and brand of recovery filter and to perform studies demonstrating suitability for this test.

Equipment	Test Microorganism, Reagents, and Media
Sterile borosilicate glass test tube with closure Stir plate, magnetic, Stir bars, sterilized Petroff-Hausser counting chamber (optional) Stopwatch Sterile pipettes/pipettors Pressure vessel with fittings Incubator 37±2 °C, with agitation Vortex mixer Filter holders to hold 47 flat disc membranes Autoclave Filter forceps Tubing Pressure gauges 0 to 100 psig (0 to 689 kPa) Biological safety cabinet (BSC) or laminar flow hood (LFH) (Optional) Ultrasonic bath, capable of producing a culture that penetrates a 0.2 µm control filter	<p><i>Acholeplasma laidlawii</i> (Sabin 1941) Edward and Freundt 1970 (<i>A. laidlawii</i>) [15] History: ATCC 23206 <- R. Wittler <- D.G.ff. Edward, PG8 <- Nat. Inst. Med. Res. London, UK (A) <- P.P. Laidlaw & W.J. Elford Collections, for example, include: ATCC® No. 23206™, CIP 75.27, NCTC 10116, DSM 23060, NBRC 14400 (formerly IFO 14400), or equivalent. Other designations: A, PG8; PG8</p> <p>The test microorganism should be identified as being of the required species by comparison to type cultures.</p> <p>Sterile deionized (DI) water Sodium Phosphate, monobasic Sodium Phosphate, dibasic Agar, purified grade Mycoplasma Broth Base Dilution blanks, for serial 10-fold dilutions, mycoplasma buffer Yeast Extract Horse Serum, heat inactivated</p>

243

244

245 **6.1.1 Preparation of media and buffer**

246 The information provided in **Table 2** below describes steps for preparing the frozen stock broth, culture medium,
 247 mycoplasma buffer and recovery agar for the challenge test.

248 **Table 2 Preparation of Media & Buffer**

Mycoplasma Buffer:	<p>Composition:</p> <table border="0"> <tr> <td>Sodium Phosphate Monobasic, CAS 7558-80-7</td> <td style="text-align: right;">3.36 g</td> </tr> <tr> <td>Sodium Phosphate Dibasic, CAS 7558-79-4</td> <td style="text-align: right;">10.22 g</td> </tr> <tr> <td>Sterile deionized water</td> <td style="text-align: right;">1 L</td> </tr> </table> <p>Preparation:</p> <ol style="list-style-type: none"> 1. Dissolve 3.36 g of Sodium Phosphate Monobasic and 10.22 g of Sodium Phosphate Dibasic in 1 L of deionized water. 2. Adjust the pH of the solution to a final pH of 7.1 ± 0.1 3. Sterilize by filtration or autoclave for 15 min @ 121 °C. 4. After sterilization, buffer can be stored at room temperature until used. <p>Prepare fresh buffer each time.</p>	Sodium Phosphate Monobasic, CAS 7558-80-7	3.36 g	Sodium Phosphate Dibasic, CAS 7558-79-4	10.22 g	Sterile deionized water	1 L
Sodium Phosphate Monobasic, CAS 7558-80-7	3.36 g						
Sodium Phosphate Dibasic, CAS 7558-79-4	10.22 g						
Sterile deionized water	1 L						

Recovery Agar:	1. Select an appropriate nutritional culture agar previously validated for <i>A. laidlawii</i> culture and titer.								
Culture Media: Mycoplasma Task Force Broth (MTFB)	<p>Composition:</p> <table data-bbox="531 324 1034 459"> <tr> <td>Mycoplasma Broth Base</td> <td>20 g</td> </tr> <tr> <td>Yeast Extract</td> <td>25 g</td> </tr> <tr> <td>Deionized water</td> <td>900 mL</td> </tr> <tr> <td>Horse Serum</td> <td>100 mL</td> </tr> </table> <p>Preparation:</p> <ol data-bbox="531 533 1310 822" style="list-style-type: none"> 1. Dissolve 20 g of mycoplasma broth base and 25 grams of yeast extract in 900 mL of deionized water. 2. Autoclave the culture medium using a validated sterilization cycle. 3. Once the broth has cooled, aseptically add 100 mL of heat inactivated horse serum. 4. Store refrigerated (4°C to 8°C). Time to be determined by the laboratory. 	Mycoplasma Broth Base	20 g	Yeast Extract	25 g	Deionized water	900 mL	Horse Serum	100 mL
Mycoplasma Broth Base	20 g								
Yeast Extract	25 g								
Deionized water	900 mL								
Horse Serum	100 mL								

249

250 **6.2 Preparation of challenge microorganism**

251 Use *Acholeplasma laidlawii* from a culture collection (see Table 1) stored at -20 °C or lower as the stock culture
 252 for challenge testing. Organism should not be used more than 15 passages from reference strain obtained from
 253 the culture collection. The stock is used to inoculate MTFB to obtain an *A. laidlawii* working culture [15,16].
 254

- 255 1. Inoculate the MTFB medium 72 hours prior to use.
- 256 2. Add 1 mL of thawed *A. laidlawii* stock per 200 mL of MTFB.
- 257 3. Incubate the broth culture, cap loosened and with gentle agitation at 37±2 °C for 72 hours.
- 258 4. (Optional) After incubation and prior to use, sonication in an ultrasonic bath may be
 259 performed.

260 **6.2.1 Preparation of the challenge suspension**

- 261 1. Prepare the *A. laidlawii* (ATCC® No. 23206™ or equivalent) challenge suspension to achieve
 262 ≥ 80% monodispersion using the above working culture.
- 263 2. Assess monodispersion by loading a bacterial counting chamber (such as a Petroff-Hauser
 264 counting chamber) as described by the manufacturer. View the cells at 1000X. Use of a green
 265 filter on the light source can facilitate this imaging.
- 266 3. Randomly select a minimum of 5 boxes on the grid. Count the number of individual vs. the
 267 number of clumped (doubles or more) microorganisms observed. At least 20 or more cells or
 268 cell clusters must be counted before determining a percent monodispersion.
- 269 4. Calculate the percent monodispersion using the following equation:

270 **% Monodispersion = 100 x Number of single cells counted/total number of bodies***
 271 **counted**

272
$$\% \text{ Monodispersion} = 100 \times \frac{\text{Number of Single Cells Counted}}{\text{Total Number of Bodies Counted}}$$

273 *Where “bodies” refers to single cells and cell clusters. One multi-celled cluster observed is
 274 counted as one body when determining total count.

275

276 5. Add sterile mycoplasma buffer to a pressure vessel sufficient for the application of 200 mL of
277 challenge suspension per test filter and control filter.

278 6. Calculate the volume of *A. laidlawii* working culture needed for the challenge suspension
279 using the following equations (based on a single filter):

280 a. Determine the required challenge concentration and multiply as necessary depending
281 on the number of filters to test:

282
$$\text{Challenge Concentration (CFU/mL)} = \frac{\text{Target Challenge Level (CFU/cm}^2\text{)} \times \text{Filter Area (cm}^2\text{)}}{\text{Total Challenge Volume (mL)}}$$

283 b. Determine the volume of *A. laidlawii* working culture required:

284
$$\text{Volume of Working Culture (mL)} = \frac{\text{Challenge Concentration (CFU/mL)} \times \text{Total Required Volume (mL)}}{\text{Working Culture Concentration (CFU/mL)}}$$

285 c. After adding the required amount of the culture to the mycoplasma buffer from step
286 b, place the vessel on a magnetic stirrer; add a sterilized magnetic stir bar, and gently
287 stir to uniformly maintain the culture in suspension throughout the duration of the
288 challenge test. Maintain the pressure vessel at ambient room temperature.

289 7. Suspend sufficient mycoplasma cells in mycoplasma buffer to yield a final minimum *A.*
290 *laidlawii* challenge level of 1.0×10^7 CFU/cm² of test filter area.
291

292 **6.2.2 Challenge test apparatus**

293 **Figure 2** presents one example of a two-filter (one-test and one positive control) challenge test apparatus for a
294 constant pressure normal flow filtration test. All components are designed to withstand at least 100 psig (689
295 kPa) and at least 135 °C.

296 In designing a test system, consideration should be given to ensure negligible pressure drop due to filter housing
297 fittings on the downstream side of the filter. Additionally, confirm that the manifold pressure (G-2) reflects the
298 target inlet pressure of 30 psi at the filter flow rates expected for the testing. Otherwise, a pressure gauge is
299 needed immediately upstream of the filter housing and, if housing outlet pressure drop is not negligible,
300 immediate downstream or one could use a differential pressure gauge connected immediately upstream and
301 immediately downstream of the filter housing. Additionally, if more than one filter at a time is tested, it must
302 be shown that the pressure differential is maintained at 30 psid for each filter. **Table 3** reflects the challenge
303 test parameters for the apparatus.

304 **Table 3 Challenge test parameters**

Challenge Test Mode:	Normal flow filtration with constant pressure
*Test Pressure:	30 psid (207 kPa)
Challenge volume for a 47 mm disc:	200 mL

*Maintain a constant test pressure by means of a pressurized vessel, and monitor the differential pressure using pressure gauges upstream of the test filter housings.

305

306 To perform the challenge test, ensure all valves are closed, then pressurize the Challenge Suspension vessel to
307 30 psi. Next, open valves to fill the challenge manifold with challenge suspension. Open the valve above each

308 filter to allow 200 mL of challenge suspension to filter while collecting the effluent in an effluent collection
 309 vessel.

310 Determine the challenge suspension influent concentration and the post-challenge effluent (filtrate) pool
 311 concentration using a previously validated *A. laidlawii* titer determination method. Where necessary, perform a
 312 serial dilution in mycoplasma buffer. The results can be reported as an LRV or a TR (Section 6.3).

313

314


315

316

317

318

Figure 2 Example of a Challenge Test Apparatus



319

320

PR-1	Pressure Regulator
FH-1	Air Filter Housing Cartridge, 0.2 µm, sterilizing grade
G-1	Pressure Gauge on Challenge Suspension Pressure Vessel
H-1	Hose 1: Deliver compressed air to Pressure Vessel 1: Challenge Suspension Vessel
H-2	Hose 2: Deliver Challenge Suspension to Challenge Manifold
CV-1	Inlet Valve to Challenge Suspension Vessel
CV-2	Outlet Valve from Challenge Suspension Vessel
G-2	Pressure Gauge on Challenge Manifold
M-1	Challenge Manifold
MV-1	Challenge Manifold Challenge Suspension Inlet Valve
MV-2, MV-3	Challenge Manifold Valves to Disc Filter Housings
MV-4	Challenge Manifold Valve to direct waste to vented vessel
FHD-1	Filter Housing for 0.2 µm control filter
FHD-2	Filter Housing for Disk Membrane (Test Sample)
EC-1	Effluent Collection Vessel
EC-2	Effluent Collection Vessel

321

322 **6.3 Reporting results**

323 Determine the challenge suspension influent concentration and the post-challenge effluent (filtrate) pool
 324 concentration using a previously validated *A. laidlawii* titer determination method. Where necessary, perform a
 325 serial dilution in mycoplasma buffer; the results can be reported as an LRV or a TR.

326 Titer reduction is the ratio of the total number of mycoplasma used to challenge the filter (influent) divided by
 327 the total number of mycoplasma that passed through the filter (effluent) using the following equation:

328
$$TR = \frac{Upstream\ Microbial\ Titer\ (CFU/mL) \times Volume\ Applied}{Downstream\ Microbial\ Titer\ (CFU/mL) \times Volume\ Filtered}$$

329

330 The Log Reduction Value (LRV) is the titer reduction expressed as a base 10 logarithm.

331
$$LRV = \log_{10} \left(\frac{Upstream\ Microbial\ Titer\ (CFU/mL) \times Volume\ Applied}{Downstream\ Microbial\ Titer\ (CFU/mL) \times Volume\ Filtered} \right)$$

332

333 The filter can be considered fully retentive (under the given conditions) when all of the filter effluent is analysed
 334 and no *A. laidlawii* is detected, where the positive control filter exhibits growth and where the challenge level
 335 is $\geq 1.0 \times 10^7$ CFU/cm².

336 Non-fully retentive filters can be considered reductive (under the given conditions) when a titer reduction (or
 337 log reduction value) can be determined as per the equations above.

338

339 **6.4 Test acceptance criteria**

340 The test is valid if it meets the following criteria:

- 341 A. **Monodispersion:** Samples of the mycoplasma challenge suspension must be $\geq 80\%$
342 monodispersed as determined microscopically. If monodispersion cannot be achieved, then do
343 not proceed with the test.
- 344 B. **Challenge Level:** A minimum challenge level of $\geq 1.0 \times 10^7$ CFU/cm² must be met. If the
345 challenge does not meet the minimum challenge concentration, then the test is invalid.
- 346 C. **Positive Control:** *A. laidlawii* must be detected in the effluent (filtrate) of the 0.2 μ m positive
347 control filter. If *A. laidlawii* is not detected in the effluent, then the challenge test is invalid.
- 348 D. **Filter Integrity:** All test article filters should pass a pre-established pre-challenge integrity
349 test. The positive control must also pass the post-challenge integrity test. For developmental
350 filters, integrity test values are recorded for future determination of allowable limits.
- 351 a. If the filter fails integrity, rewet the filter according to the manufacturer's
352 recommendations and repeat the test. If the filter integrity test fails again, then proceed to
353 Step b.
- 354 b. (Optional unless there is a failure in Step a.)
355 Flush the filter using a lower surface tension solution, such as alcohol in water, as
356 recommended by the filter manufacturer, and perform the integrity test using the lower
357 surface tension solution. If the filter integrity test fails again, then the challenge test is
358 invalid.
359
- 360

361 **7 Bibliography**

- 362 1. Drexler, H. and C. Uphoff, Mycoplasma contamination of cell cultures: Incidence, sources, effects,
363 detection, elimination and prevention. Cytotechnology, 2006. 39(2): p. 75-90.
- 364 2. Chandler, D. and e. al, Historical Overview of Mycoplasma Testing for Production of Biologics. Am Pharm
365 Rev, 2011. 14(4).
- 366 3. Parenteral Drug Association, Technical Report No 50: Alternative Methods for Mycoplasma Testing. 2008,
367 PDA: Bethesda, MD.
- 368 4. United States Pharmacopeia, General Chapter <1043> Ancillary Materials for Cell, Gene, and Tissue-
369 Engineered Products. USP31/NF26. 2011,
- 370 5. Windsor, H. and e. al, The Growth and Long Term Survival of Acholeplasma laidlawii in Media Products
371 Used in Biopharmaceutical Manufacturing. Biologicals, 2010. 38: p. 204-210.
- 372 6. Kljavin, I. Mycoplasma Contamination in TSB Derived from Plant Peptones. in Proceedings from the PDA
373 Workshop on Mycoplasma Contamination by Plant Peptone. 2007.
- 374 7. U.S. Food and Drug Administration, Questions and Answers on Current Good Manufacturing Practices,
375 Good Guidance Practices, Level 2 Guidance - Production and Process Controls.2019, U.S. Department
376 of Health and Human Services: Rockville, Md.
- 377 8. Folmsbee, M. and e. al, The Development of a Microbial Challenge Test with Acholeplasma laidlawii To
378 Rate Mycoplasma-Retentive Filters by Filter Manufacturers. PDA J Pharm Sci and Tech, 2014. 68: p.
379 281-296.
- 380 9. Parenteral Drug Association, Technical Report No. 26 (Revised 2008): Sterilizing Filtration of Liquids.
381 2008, PDA: Bethesda, MD.
- 382 10. Parenteral Drug Association, Technical Report No. 75 Consensus Method for Rating 0.1µm Mycoplasma
383 Reduction Filters. 2016, PDA: Bethesda, MD.
- 384 11. ASTM International, ASTM F838-20 Standard Test Method for Determining Bacterial Retention of
385 Membrane Filters Utilized for Liquid Filtration, ASTM International: West Conshohocken, PA, 2020,
386 www.astm.org.
- 387 12. U.S. Food and Drug Administration, Guidance for Industry: Sterile Drug Products Produced by Aseptic
388 Processing—Current Good Manufacturing Practice, , 2004, U.S. Department of Health and Human
389 Services: Rockville, Md.
- 390 13. Bowman, F.W., M.P. Calhoun, and M. White, Microbiological methods for quality control of membrane
391 filters. J Pharm Sci, 1967. 56(2): p. 222-5.
- 392 14. Bowman, F.W. and S. Holdowsky, Production and control of a stable penicillinase. Antibiot Chemother
393 (Northfield), 1960. 10: p. 508-14.
- 394 15. NCBI, Acholeplasma laidlawii (Sabin 1941) Edward and Freundt 1970. NCBI Taxonomy Library, (ID:
395 2148).
- 396 16. United States Pharmacopeia, General Chapter USP-NF 63 Mycoplasma Tests. Vol. USP-NF 63, 2020,
397 Rockville, MD.